Richard Marshall
Förmögenhet: 22 417 $ per 2026-05-31
Förmögenhet: 22 417 $ per 2026-05-31
Richard Marshall is Chief Executive Officer at Juvenescence Ltd. and Juvenescence Therapeutics Ltd. since 2023.
Since 2024, Dr. Marshall is an Independent Director at Serina Therapeutics, Inc. From 2019 to 2023, Dr. Marshall was SVP, Global Head-Respiratory & Immunology at AstraZeneca PLC.
From 2002 to 2018, Dr. Marshall was Vice President-Fibrosis Research & Development at GSK Plc.
Dr. Marshall completed undergraduate and doctorate degrees at University College London.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
0,08 % | 2026-06-17 | 12 183 ( 0,08 % ) | 22 417 $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Verkställande Direktör | 2023-01-16 |
| Företag | Position | Slut |
|---|---|---|
| ASTRAZENECA PLC | Företagsledare/Principal | 2023-01-01 |
| GSK PLC | Företagsledare/Principal | 2018-01-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Välj din utgåva
All finansiell information anpassad till den nationella nivån